Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 27, 2026
HeartFlow (HTFL) Stock Jumps +92.9% in 30 Days on Strong Q2 Results

HeartFlow (HTFL) Stock Jumps +92.9% in 30 Days on Strong Q2 Results

Key Takeaways

  • HeartFlow shares rose approximately 92.9% over the trailing 30 days, climbing from about $25.37 to roughly $48.94.
  • The rally was driven by second-quarter 2026 results that beat expectations and a meaningful increase to full-year revenue guidance.
  • Several sell-side firms raised price targets following the report, reinforcing positive sentiment toward the stock.
  • The company remains unprofitable, so growth execution and continued adoption of its Plaque Analysis product remain central to the investment case.

HeartFlow (HTFL) Company Overview and Market Position

HeartFlow, Inc. is a commercial-stage medical technology company based in San Francisco that uses artificial intelligence and advanced computational fluid dynamics to deliver non-invasive solutions for diagnosing and managing coronary artery disease (CAD). Its HeartFlow One platform builds a personalized 3D model of a patient's coronary arteries from a single coronary computed tomography angiography (CCTA) image, and includes Roadmap Analysis, FFRCT Analysis, and Plaque Analysis software. The company has accumulated one of the world's largest databases of annotated cardiac CT images—more than 200 million images—and has helped guide care for over 650,000 patients worldwide. HeartFlow completed its initial public offering in August 2025 and generates the large majority of its revenue in the United States. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

HeartFlow (HTFL) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, HTFL advanced roughly 92.9%, rising from a closing price near $25.37 in late July to about $48.94 by late August. Most of that move occurred in a matter of days after the company reported quarterly results, with shares jumping more than 35% in a single session and continuing to trade near 52-week highs afterward.

The quarterly picture tells a similar but more volatile story. Roughly three months earlier, the stock traded near $28, meaning it has gained on the order of 72% over the period. That broader trend was not linear: shares declined through much of July into the low-to-mid $20s before rebounding sharply once second-quarter results and revised guidance reset investor expectations.

What Drove HTFL Stock Price in the Last 30 Days

The primary catalyst was HeartFlow's second-quarter 2026 earnings report. Revenue rose 48% year over year to approximately $64.1 million, ahead of the consensus estimate near $56.6 million, and adjusted loss per share of $0.07 was narrower than the roughly $0.13 loss analysts had expected. Gross margin reached record levels, expanding to 83.0% on a GAAP basis and 83.3% on a non-GAAP basis.

Management also raised its full-year 2026 revenue guidance to between $246 million and $250 million, up from a prior range of $228 million to $232 million, implying roughly 40% to 42% growth, and lifted its full-year gross margin target. Analysts responded by raising price targets—Stifel moved to $45 from $40 with a Buy rating, JPMorgan raised its target to $45 from $35 with an Overweight rating, and Wells Fargo increased its target to $39 from $37. William Blair's Brandon Vazquez maintained an Outperform rating, noting the guidance increase was roughly twice the size of the earnings beat. From what I see, this level of analyst support adds meaningful weight to the recent move.

What Drove HTFL Stock Performance Over the Last Quarter

Beyond the immediate earnings reaction, the stock's three-month advance reflects a broader narrative of accelerating adoption of AI-enabled cardiac diagnostics. HeartFlow's core FFRCT business has remained durable, while Plaque Analysis has emerged as a fast-growing second revenue engine following expanded reimbursement coverage. The company also launched PCI Navigator, an AI-driven pre-procedure planning tool for interventional cardiologists, and has pointed to a substantially under-penetrated CCTA market as a source of continued growth.

Institutional participation has also increased. According to third-party data, the number of hedge funds holding HeartFlow shares rose from 16 to 25 between consecutive quarters, with combined holdings growing by more than half. At the same time, the stock remains unprofitable, and valuation has expanded alongside the rally, leaving the shares sensitive to any shortfall in adoption or reimbursement trends.

HTFL Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to focus on the pace of Plaque Analysis adoption, including the company's progress toward its target of roughly 1,200 active sites, and on whether FFRCT case volumes sustain their current growth. Reimbursement developments, new clinical data, and updates to full-year guidance will also matter, as will the company's path toward narrowing operating losses and reaching cash-flow profitability. Because the stock has re-rated sharply, execution against the raised revenue outlook and continued gross-margin expansion will be closely monitored, alongside any signs that adoption is slowing or that valuation has outrun fundamentals. I’m watching this closely as the next few quarters will test whether the momentum holds.

Exploring Tickeron’s Trending AI Robots for Additional Perspective

In my own research process, I occasionally review Tickeron’s Trending AI Robots page to see how automated strategies are performing across various tickers. It offers a focused look at top bots without requiring a full scan of every option available, which can provide a useful complement when evaluating names like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HTFL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


HTFL in upward trend: 10-day moving average crossed above 50-day moving average on August 14, 2026

The 10-day moving average for HTFL crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

HTFL moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for HTFL moved above the 200-day moving average on August 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HTFL advanced for three days, in of 70 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 41 cases where HTFL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for HTFL moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 12 cases where HTFL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HTFL as a result. In of 23 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HTFL turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 9 similar instances when the indicator turned negative. In of the 9 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTFL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HTFL broke above its upper Bollinger Band on August 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HTFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.837) is normal, around the industry mean (7.299). HTFL has a moderately low P/E Ratio (0.000) as compared to the industry average of (45.110). HTFL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.482). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. HTFL's P/S Ratio (19.531) is slightly higher than the industry average of (6.025).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.81B. The market cap for tickers in the group ranges from 708 to 42.88B. VEEV holds the highest valuation in this group at 42.88B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -3%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 19%. ONMD experienced the highest price growth at 20%, while PHR experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was -72% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 74
Price Growth Rating: 53
SMR Rating: 86
Profit Risk Rating: 98
Seasonality Score: -29 (-100 ... +100)
View a ticker or compare two or three
HTFL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Profile
Details
Industry
N/A
Address
331 East Evelyn Avenue
Phone
+1 650 241-1221
Employees
843
Web
https://www.heartflow.com
Interact to see
Advertisement
Shares of CRDO surged +11.90% on March 5, 2026, closing at $114.74 versus a prior close of $102.54. Primary catalyst: Strong Q3 fiscal 2026 earnings reported on March 2, with revenue of $407 million beating consensus estimates by more than $19 million and non-GAAP EPS of $1.07 surpassing forecasts by $0.29.
SPY is trading down approximately -1.30% in Friday premarket, slipping from the prior session's close of $681.31 to around $677–$678. The primary catalyst is a sharply negative February 2026 Nonfarm Payrolls report, which showed a decline of 92,000 jobs — a massive miss versus the consensus forecast of +50,000.
WAL shares dropped approximately 12% in early trading on March 6, 2026, from a prior close of ~$80.74 to roughly ~$71, marking one of the stock's sharpest single-session declines in recent months. The primary catalyst was a surprise announcement that Jefferies Financial Group declined to make a $126.4 million payment owed to Western Alliance Bank under a forbearance agreement tied to the LAM Trade Finance loan portfolio.
MRVL shares surged approximately +15% at the open on March 6, 2026, after closing at $75.68 the prior session. The primary catalyst was a strong Q4 fiscal 2026 earnings report released after the close on March 5, with non-GAAP EPS of $0.80 beating the $0.79 consensus estimate and revenue of $2.219 billion exceeding expectations.
Shares of Day One Biopharmaceuticals surged approximately +65.57% on March 6, 2026, rising from a prior close of $12.78 to an intraday price around $21.16. The primary catalyst driving the session's gains is acquisition and takeover speculation, with reports circulating that Day One may be a buyout target.
GAP shares fell approximately 13% in early trading on March 6, 2026, following the company's Q4 fiscal 2025 earnings report released after market close on March 5. Gap met Wall Street's Q4 estimates on both earnings per share and revenue, but fiscal 2026 guidance fell short of analyst expectations.
Shares of Red Cat Holdings surged approximately +22% in early Friday trading on March 6, 2026, building on a powerful week of momentum in defense drone stocks. The primary catalyst is escalating geopolitical conflict — U.S. and Israeli military strikes on Iran, which dramatically boosted investor appetite for domestic drone and defense technology companies.
The primary catalyst for the decline was the pricing of a secondary offering of roughly 9 million shares at about 22.25 dollars per share by Ingram Holdco, an affiliate of Platinum Equity, with all proceeds going to the selling shareholder and not to Ingram Micro itself. Investors often view such secondary offerings as short‑term bearish because they increase the freely tradable float and signal that a major holder is cashing out part of its stake, even if the company’s operations remain intact.
Rumble reported Q4 2025 revenue of about 27.1 million dollars, below consensus expectations near 29 million dollars and down roughly 10% year over year, confirming that top‑line momentum has stalled. GAAP EPS came in at a loss of around 0.13 dollars, missing analyst estimates by roughly 0.05 dollars and underscoring that the platform remains far from break‑even despite prior cost cuts and efficiency efforts.
Tronox’s Q4 2025 non‑GAAP EPS came in at a loss of about 0.60 dollars, missing expectations by roughly 0.02 dollars, while revenue of around 730 million dollars grew about 8% year over year, showing volume resilience but weak earnings power.
Defense budgets worldwide are surging — global military spending topped $2.2 trillion in 2023, a record high — while semiconductor demand is projected to reach a $1 trillion industry by 2030. At the intersection of these two mega-trends sits one of Tickeron's most strategically focused AI Trading Robots: the XAR, ITA, SOXL – AI Trading Agent (3 Tickers), 15min.
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.
CRCL surged +8.66% on Monday, March 9, 2026, rising from a prior close of $101.94 to trade at $110.77 intraday. The primary catalyst is a landmark stablecoin milestone: Circle's USDC overtook Tether as the dominant stablecoin by transfer volume, accounting for approximately 70% of all stablecoin transfer activity as total stablecoin transfers hit $1.8 trillion in February.
Carnival Corporation (CCL) shares fell approximately -7.60% in Monday's session, dropping from a Friday close of $25.79 to around $23.83. The primary catalyst is a broad market sell-off driven by intensifying recession fears, with the S&P 500 and consumer discretionary names bearing the brunt of the pressure.
Shares of Bloom Energy (BE) are surging approximately +10.30% in Monday's session, rebounding sharply from a steep -15.50% selloff on Friday, March 6, 2026. Friday's decline was triggered by an Oracle-OpenAI data center project update that spooked energy infrastructure investors; Monday's move reflects aggressive dip-buying and a sentiment reset.
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.